Skip to main content
Withdrawn

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

By April 24, 2017No Comments

Condition

Non Small Cell Lung Cancer|Advanced Triple Negative Breast Cancer|Small Cell Lung Cancer|Urothelial Cancer|Mesothelioma|Malignant Melanoma

Estimated Enrollment: 0

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CASE2Y16

Study First Received: January 19, 2016

Last Updated: December 5, 2016

Estimated Primary Completion Date: July 2018

 

Primary Outcome Measures:

Dose Limiting Toxicity|Objective Response Rate for combination therapy|Median Duration of Response|Median time to tumor response|Median time of progression free survival|Median Overall Survival

Sponsors and Collaborators:

Case Comprehensive Cancer Center

Website Link: https://ClinicalTrials.gov/show/NCT02661100

Leave a Reply

Close Menu